Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the pharmacokinetic profile, the effect of rennin inhibition and the
relationship among pharmacokinetics, renin-angiotensin system (RAS) biomarkers, and blood
pressure lowering effects of oral doses of SPP100 in Japanese patients with mild to moderate
essential hypertension. Safety will also be evaluated.